Medication info
Myungmoon Linagliptin Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Myungmoon Linagliptin Duo Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Oval extended-release tablet, white to nearly white with '25LM' engraved on one side
Packaging
28 tablets/box (7 tablets/PTP x 4)
Approval status
Active

MFDS item code 202400616 · Approved 2024.03.22 · Insurance code 649808250

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining linagliptin and metformin. Taking it in conjunction with meals and exercise enhances its effectiveness. It helps stabilize blood sugar levels, reducing the risk of complications related to diabetes. Regular use can assist in maintaining healthy blood sugar management. This medication improves blood sugar control in type 2 diabetes patients.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication consists of two main ingredients that mainly assist with blood sugar control. However, there is a risk of rare but serious lactic acidosis, so caution is necessary. This medication should not be used in certain patients. For example, it should not be administered to individuals with an allergy to this medication or any of its components, those with type 1 diabetes, severe kidney dysfunction, severe liver dysfunction, acute infection, or acute myocardial infarction. Additionally, patients who are acutely or chronically alcohol intoxicated, those in very poor nutritional states, patients with acute and unstable heart failure, and pregnant women who may pose a risk to the fetus should avoid this medication. When administering this medication, it is important to pay attention to symptoms of hypoglycemia. The risk of hypoglycemia may increase, especially when taken with insulin or sulfonylureas, so blood sugar levels should be monitored frequently and doses adjusted as necessary. Lactic acidosis is very rare but can be fatal, so if symptoms such as sudden abdominal pain, muscle weakness, breathing difficulties, or lethargy appear, immediate consultation with medical personnel is necessary. Patients with decreased kidney function may have difficulty excreting this medication, increasing the risk of side effects, so renal function tests should be conducted regularly before and during treatment, and this medication should not be used if kidney function falls below a certain level. Patients with poor cardiac function or heart failure should also use this medication with caution, and cardiac status should be monitored regularly. When intravenous iodinated contrast agents used in radiological examinations are administered, they may affect kidney function and increase the risk of side effects from this medication, so it is advisable to discontinue this medication for a certain period before and after the examination. In cases of surgery, this medication should be discontinued 48 hours prior to surgery and should only be resumed after renal function has recovered post-surgery. During treatment with this medication, acute pancreatitis or vesicular skin diseases may occur, so if persistent severe abdominal pain or skin abnormalities arise, notify a doctor immediately. The metformin component can interfere with vitamin B12 absorption, thus regular testing for vitamin B12 deficiency during long-term use is advisable. This medication should not be crushed or chewed but should be swallowed whole, and it is normal for the tablet coating to be excreted in feces. Due to potential drug interactions, especially with medications that affect kidney function or blood sugar control, patients should inform medical personnel and take precautionary measures. Use of this medication is not recommended during pregnancy or while breastfeeding, and if planning to become pregnant, appropriate treatment options should be discussed with a healthcare professional. For the safety of children, this medication should be stored out of reach of children and in a dry place. In case of overdose, serious side effects such as lactic acidosis may occur, necessitating immediate medical treatment.

Side effects

Severe lactic acidosis, hypoglycemia, vascular edema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic episodes, taste disorder, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigoid-like lesions, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reactions, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, septicemia, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, renal transplant failure, pneumonia, hypertension, anxiety, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid goiter, anemia, nausea, gastroesophageal reflux disease, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, rotator cuff syndrome, increased serum triglycerides, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase activity, pruritus, benign prostatic hyperplasia, confusional state, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and safety.

Appearance and packaging

Appearance

Oval extended-release tablet, white to nearly white with '25LM' engraved on one side

Package unit

28 tablets/box (7 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.